Company intelligence / Profile preview
Renovis
South San Francisco, California, United Statesrenovis.net ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Renovis was developing prescription drugs for neurological diseases and cancer. Their lead programs included VR1 antagonists for pain, urinary incontinence, and asthma, and P2X7 antagonists for rheumatoid arthritis, irritable bowel syndrome, and chronic obstructive pulmonary disease. Both programs were expected to enter human clinical trials in 2008.
- Therapeutic areas
- GastroenterologyPulmonologyNephrologyImmunologyOncologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Pfizer, Inc.
Beyond the preview
Go deeper on Renovis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Renovis.